Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23601663 | 0.94 | MEN1 (0.40) | MEN1KMT2ARAB9ALMNAALDH1A1 | |
| SCHEMBL27573586 | 0.93 | MEN1 (0.46) | MEN1KMT2ARAB9ALMNAALDH1A1 | |
| SCHEMBL19089846 | 0.91 | PGR (0.42) | MEN1KMT2ARAB9ALMNAALDH1A1 | |
| SCHEMBL6202886 | 0.87 | LMNA (0.38) | MEN1KMT2ARAB9ALMNAALDH1A1 | |
| SCHEMBL23040803 | 0.84 | MEN1 (0.36) | MEN1KMT2ARAB9ALMNAALDH1A1 | |
| SCHEMBL14120878 | 0.83 | LMNA (0.44) | MEN1KMT2ARAB9ALMNAALDH1A1 | |
| SCHEMBL2611715 | 0.83 | MEN1 (0.45) | MEN1KMT2ARAB9ALMNAALDH1A1 | |
| SCHEMBL19149745 | 0.81 | MEN1 (0.54) | MEN1KMT2ARAB9ALMNAALDH1A1 | |
| Potassium Ion SCHEMBL31649385 | 0.81 | MEN1 (0.50) | MEN1KMT2ARAB9ALMNAALDH1A1 | |
| Adamantane SCHEMBL28719949 | 0.76 | CA2 (0.45) | MEN1KMT2ALMNAENPP3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720037-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| US-20250160195-A1 | LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE HETEROCYCLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-05-15 | — | — | US | disclosed |
| CN-119954851-A | Light-emitting device, electronic apparatus, electronic device, and heterocyclic compound | 三星显示有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025057775-A1 | MATERIAL FOR PHOTOELECTRIC CONVERSION ELEMENT FOR IMAGING ELEMENT, AND IMAGING ELEMENT | 東ソー株式会社 | 2025-03-20 | — | — | WO | disclosed |
| US-20240164208-A1 | ORGANIC COMPOUND AND LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-05-16 | — | — | US | disclosed |
| CN-111825558-B | Novel compound and organic light-emitting device | 乐金显示有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-11844270-B2 | Compound and organic light emitting device including the same | LG DISPLAY CO., LTD. (KR) | 2023-12-12 | — | — | US | disclosed |
| US-11844270-B2 | Compound and organic light emitting device including the same | LG DISPLAY CO., LTD. (KR) | 2023-12-12 | — | — | US | disclosed |
| US-11844270-B2 | Compound and organic light emitting device including the same | LG DISPLAY CO., LTD. (KR) | 2023-12-12 | — | — | US | disclosed |
| US-20230157155-A1 | LIGHT EMITTING DEVICE AND AMINE COMPOUND FOR LIGHT EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| EP-1117628-B1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN INC (US) | 2003-11-19 | — | — | EP | disclosed |
| EP-1192122-B1 | BENZENE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI SYNTHELABO (FR) | 2003-10-22 | — | — | EP | disclosed |
| US-6482986-B1 | Benzene derivatives, preparation method and pharmaceutical compositions containing same | SANOFI-SYNTHELABO (FR) | 2002-11-19 | — | — | US | disclosed |
| US-6403638-B1 | COMPOUND FOR USE IN TREATING SKIN DISEASES AND DISORDERS, AND FOR TREATING HYPERVITAMINOSIS A SYNDROME | ALLERGAN SALES, INC. | 2002-06-11 | — | — | US | disclosed |
| EP-1192122-A1 | BENZENE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001070662-A2 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN , INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1117628-A1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | Allergan Sales, Inc. (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000076953-A1 | BENZENE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2000-12-21 | — | — | WO | disclosed |
| US-6147224-A | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | ALLERGAN SALES, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| WO-2000020370-A1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN SALES, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844270-B2 | Compound and organic light emitting device including the same | TMEM109, CRY1, VDAC1 | MEN1 1603/4885KMT2A 2450/4885RAB9A 1147/4885 |
| US-20240164208-A1 | ORGANIC COMPOUND AND LIGHT-EMITTING DEVICE INCLUDING THE SAME | OR10J3, LEF1, L1CAM | MEN1 1358/4885KMT2A 1780/4885RAB9A 2469/4885 |
| US-20230157155-A1 | LIGHT EMITTING DEVICE AND AMINE COMPOUND FOR LIGHT EMITTING DEVICE | CRY1, SLC1A2, CHRM1 | MEN1 463/4885KMT2A 381/4885RAB9A 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.